This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Buybacks, bids, downgrades and drama peppered the news, prompting a few spikes in a generally flat health sector Wednesday.

Biogen Idec (BIIB) pledged a $3 billion buyback of up to 57 million shares of its own stock, reducing the share count by 16%. It will buy them for between $47 and $53 a share, depending on how many shares are tendered by shareholders. The Cambridge, Mass., biotech company said the buyback, which started today, will run through June 26. The stock climbed $2.75, or 5.6%, to $51.95.

The Amex Biotechnology Index, which includes Biogen, was up 1.39, or 0.2%, to 820.01.

Shares of Novacea (NOVC) were up $5.90, or 73%, by Wednesday afternoon, after having risen more than 100% earlier in the day. The stock soared on the news that the California-based biotech company struck an agreement with Schering-Plough (SGP) regarding prostate cancer treatment candidate Asentar. Schering-Plough was down 38 cents, or $1.10, to $32.37.

Also up was CytRx Corp (CYTR - Get Report), which said that after favorable preclinical results and earlier clinical data, it plans to move into a phase II clinical trial for iroxanadine for diabetic foot ulcers. The Los Angeles-based biopharmaceutical company said subject to clearance from the Food and Drug Administration, the study will commence in the first half of 2008. The stock climbed 22 cents, or 6.3%, to $3.73.

Bioenvision (BIVN) was the center of drama Wednesday after three downgrades and a letter from a key shareholder, SCO Capital, proclaiming Genzyme's (GENZ) $345 million bid inadequate. Bioenvision shares were up 21 cents, or 3.8%, to $5.80. Genzyme was down 60 cents, or 0.9%, to $61.98.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
NOVC $0.30 4.83%
BIB $90.88 0.18%
ALKS $63.07 -2.62%
CYTR $3.66 -1.61%
MYL $70.12 0.60%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs